The history and future prospective of haplo-identical stem cell transplantation

References

• Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA-matched donor. Transplantation 1995; 60: 778–83
   PubMed Web of Science ®Google Scholar
• Heemskerk MB, van Walraven SM, Cornelissen JJ, et al. How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more! Bone Marrow Transplant 2005; 35: 645–52
   PubMed Web of Science ®Google Scholar
• Tiercy JM, Nicoloso G, Passweg J, et al. The probability of identifying a 10/10 HLA allele-matched unrelated donor is highly predictable. Bone Marrow Transplant 2007; 40: 515–22
   PubMed Web of Science ®Google Scholar
• Powles RL, Morgenstern GR, Kay HE, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1983; 1: 612–5
   PubMed Web of Science ®Google Scholar
• Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765–71
   PubMed Web of Science ®Google Scholar
• Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767–77
   PubMed Web of Science ®Google Scholar
• Friedrich W, Goldmann SF, Vetter U, et al. Immunoreconstitution in severe combined immunodeficiency after transplantation of HLA-haploidentical, T-cell-depleted bone marrow. Lancet 1984; 1: 761–4
   PubMed Web of Science ®Google Scholar
• Mehta J, Singhal S, Gee AP, et al. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Bone Marrow Transplant 2004; 33: 389–96
   PubMed Web of Science ®Google Scholar
• Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997; 89: 3864–72
   PubMed Web of Science ®Google Scholar
• Aversa F, Martelli MM, Reisner Y. Use of stem cells from mismatched related donors. Curr Opin Hematol 1997; 4: 419–22
   PubMedGoogle Scholar
• Bachar-Lustig E, Rachamim N, Li HW, et al. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995; 1: 1268–73
   PubMed Web of Science ®Google Scholar
• Rachamim N, Gan J, Segall H, et al. Tolerance induction by ‘megadose’ hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 1998; 65: 1386–93
   PubMed Web of Science ®Google Scholar
• Gur H, Krauthgamer R, Berrebi A, et al. Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34(+) cells. Blood 2002; 99: 4174–81
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical ‘three-loci’ incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948–55
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186–93
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Lang P, Schumm M, et al. Isolation and transplantation of autologous peripheral CD34+ progenitor cells highly purified by magnetic-activated cell sorting. Bone Marrow Transplant 1998; 21: 987–93
   PubMed Web of Science ®Google Scholar
• Schumm M, Lang P, Taylor G, et al. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device. J Hematother 1999; 8: 209–18
   PubMedGoogle Scholar
• Handgretinger R, Klingebiel T, Lang P, et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001; 27: 777–83
   PubMed Web of Science ®Google Scholar
• Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447–54
   PubMed Web of Science ®Google Scholar
• Walker I, Shehata N, Cantin G, et al. Canadian multicenter pilot trial of haploidentical donor transplantation. Blood Cells Mol Dis 2004; 33: 222–6
   PubMed Web of Science ®Google Scholar
• Redei I, Langston AA, Lonial S, et al. Rapid hematopoietic engraftment following fractionated TBI conditioning and transplantation with CD34(+) enriched hematopoietic progenitor cells from partially mismatched related donors. Bone Marrow Transplant 2002; 30: 335–40
   PubMed Web of Science ®Google Scholar
• Peters C, Matthes-Martin S, Fritsch G, et al. Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment. Leukemia 1999; 13: 2070–8
   PubMed Web of Science ®Google Scholar
• Yamasaki S, Ohno Y, Taniguchi S, et al. Allogeneic peripheral blood stem cell transplantation from two- or three-loci-mismatched related donors in adult Japanese patients with high-risk hematologic malignancies. Bone Marrow Transplant 2004; 33: 279–89
   PubMed Web of Science ®Google Scholar
• Kim HJ, Min WS, Kim YJ, et al. Haplotype mismatched transplantation using high doses of peripheral blood CD34+ cells together with stratified conditioning regimens for high-risk adult acute myeloid leukemia patients: a pilot study in a single Korean institution. Bone Marrow Transplant 2005; 35: 959–64
   PubMedGoogle Scholar
• Ruggeri L, Mancusi A, Burchielli E, et al. Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation. Semin Cancer Biol 2006; 16: 404–11
   PubMed Web of Science ®Google Scholar
• Velardi A, Ruggeri L, Moretta L. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol 2002; 23: 438–44
   PubMed Web of Science ®Google Scholar
• Farag SS, Fehniger TA, Ruggeri L, et al. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935–47
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Mancusi A, Capanni M , et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007 1;110:433–40.
   PubMed Web of Science ®Google Scholar
• Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172: 644–50
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–100
   PubMed Web of Science ®Google Scholar
• Gordon PR, Leimig T, Mueller I, et al. A large-scale method for T cell depletion: towards graft engineering of mobilized peripheral blood stem cells. Bone Marrow Transplant 2002; 30: 69–74
   PubMed Web of Science ®Google Scholar
• Barfield RC, Otto M, Houston J, et al. A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 2004; 6: 1–6
   PubMed Web of Science ®Google Scholar
• Hale GA, Kasow KA, Gan K, et al. Haploidentical stem cell transplantation with CD3 depleted mobilized peripheral blood stem cell grafts for children with hematologic malignancies. ASH Annu Meet Abstr 2005; 106: 2910
   Google Scholar
• Hale GA, Kasow KA, Madden R, et al. Mismatched family member donor transplantation for patients with refractory hematologic malignancies: long-term followup of a prospective clinical trial. ASH Annu Meet Abstr 2006; 108: 3137
   Google Scholar
• Chen X, Hale GA, Barfield R, et al. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br J Haematol 2006; 135: 524–32
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Chen X, Pfeiffer M, et al. Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation. Ann NY Acad Sci 2007; 1106: 279–89
   PubMed Web of Science ®Google Scholar
• Bethge WA, Faul C, Bornhauser M, et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update. Blood Cell Mol Dis 2008; 40: 13–9
   PubMed Web of Science ®Google Scholar
• Guinan EC, Boussiotis VA, Neuberg D, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med 1999; 340: 1704–14
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007; 25: 690–7
   PubMed Web of Science ®Google Scholar
• Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006; 38: 291–7
   PubMed Web of Science ®Google Scholar
• Ogawa H, Ikegame K, Yoshihara S, et al. Unmanipulated HLA 2–3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006; 12: 1073–84
   PubMed Web of Science ®Google Scholar
• O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8: 377–86
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Guenther W, Gyurkocza B, et al. Tolerance and chimerism. Transplantation 2003; 75(Suppl 9)26–31
   Web of Science ®Google Scholar
• Hauer J, Tosi S, Schuster FR, et al. Graft versus leukemia effect after haploidentical HSCT in a MLL-negative infant AML with HLXB9/ETV6 rearrangement. Pediatr Blood Cancer 2008; 50: 921–3
   PubMed Web of Science ®Google Scholar
• van Rood JJ, Loberiza FR, Jr, Zhang MJ, et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood 2002; 99: 1572–7
   PubMed Web of Science ®Google Scholar
• Obama K, Utsunomiya A, Takatsuka Y, Takemoto Y. Reduced-intensity non-T-cell depleted HLA-haploidentical stem cell transplantation for older patients based on the concept of feto-maternal tolerance. Bone Marrow Transplant 2004; 34: 897–9
   PubMed Web of Science ®Google Scholar
• Ichinohe T, Teshima T, Matsuoka K, et al. Fetal-maternal microchimerism: impact on hematopoietic stem cell transplantation. Curr Opin Immunol 2005; 17: 546–52
   PubMed Web of Science ®Google Scholar
• Cashen AF, Lazarus HM, Devine SM. Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?. Bone Marrow Transplant 2007; 39: 577–88
   PubMed Web of Science ®Google Scholar
• Leung W, Iyengar R, Triplett B, et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005; 174: 6540–5
   PubMed Web of Science ®Google Scholar
• Stern M, Ruggeri L, Mancusi A , et al Survival after T-cell depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008; Epub ahead of print.
   Google Scholar
• Kolb HJ, Bigalke I, Tischer J, et al. Risk factors of HLA-haploidentical transplantation using the combination of unmodified marrow and CD6-depleted G-CSF mobilized blood cells. ASH Annu Meet Abstr 2005; 106: 2907
   Google Scholar
• Chaleff S, Otto M, Barfield RC, et al. A large-scale method for the selective depletion of alpha/beta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy 2007; 9: 746–54
   PubMed Web of Science ®Google Scholar
• Meeh PF, King M, O'Brien RL, et al. Characterization of the gamma/delta T cell response to acute leukemia. Cancer Immunol Immunother 2006; 55: 1072–80
   PubMed Web of Science ®Google Scholar
• Godder KT, Henslee-Downey PJ, Mehta J, et al. Long term disease-free survival in acute leukemia patients recovering with increased gamma/delta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 2007; 39: 751–7
   PubMed Web of Science ®Google Scholar
• Chen X, Handgretinger R, Hale GA. Molecular monitoring of immune reconstitution after haploidentical stem cell transplantation. Curr Stem Cell Res Ther 2008; 3: 75–8
   PubMed Web of Science ®Google Scholar
• Volpi I, Perruccio K, Tosti A, et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 2001; 97: 2514–21
   PubMed Web of Science ®Google Scholar
• Chen X, Barfield R, Benaim E, et al. Prediction of T-cell reconstitution by assessment of T-cell receptor excision circle before allogeneic hematopoietic stem cell transplantation in pediatric patients. Blood 2005; 105: 886–93
   PubMed Web of Science ®Google Scholar
• Wils EJ, Cornelissen JJ. Thymopoiesis following allogeneic stem cell transplantation: new possibilities for improvement. Blood Rev 2005; 19: 89–98
   PubMed Web of Science ®Google Scholar
• Amrolia PJ, Muccioli-Casadei G, Huls H, et al. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006; 108: 1797–808
   PubMed Web of Science ®Google Scholar
• Feuchtinger T, Richard C, Joachim S, et al. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 2008; 31: 199–206
   PubMed Web of Science ®Google Scholar
• Einsele H, Kapp M, Grigoleit GU. CMV-specific T cell therapy. Blood Cells Mol Dis 2008; 40: 71–5
   PubMed Web of Science ®Google Scholar
• Beck O, Topp MS, Koehl U, et al. Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood 2006; 107: 2562–9
   PubMed Web of Science ®Google Scholar
• Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106: 4397–406
   PubMed Web of Science ®Google Scholar
• Bader P, Hancock J, Kreyenberg H, et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 2002; 16: 1668–72
   PubMed Web of Science ®Google Scholar
• Klingebiel T, Lang P, Schumm M, et al. Experiences with haploidentical stem cell transplantation in children with acute lymphoblastic leukemia. Pathol Biol (Paris) 2005; 53: 159–61
   PubMedGoogle Scholar
• Terme M, Ullrich E, Delahaye NF, et al. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 2008; 9: 486–94
   PubMed Web of Science ®Google Scholar
• Huang XJ, Wang Y, Liu DH , et al Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia: feasibility and safety study. J Clin Immunol 2008; Epub ahead of print.
   Web of Science ®Google Scholar
• Sprangers B, Van WB, Fevery S, et al. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. Nat Clin Pract Oncol 2007; 4: 404–14
   PubMedGoogle Scholar
• Lang P, Barbin K, Feuchtinger T, et al. Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts. Blood 2004; 103: 3982–5
   PubMedGoogle Scholar
• Schumm M, Feuchtinger T, Pfeiffer M, et al. Flow cytometry with anti HLA-antibodies: a simple but highly sensitive method for monitoring chimerism and minimal residual disease after HLA-mismatched stem cell transplantation. Bone Marrow Transplant 2007; 39: 767–73
   PubMed Web of Science ®Google Scholar